Distinguished in Upper Tract Urothelial Carcinoma (UTUC)

Dr. Timothy A. Yap

Oncology
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
1515 Holcombe Blvd, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Yap is an Oncologist in Houston, Texas. Dr. Yap is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Lung Cancer, Metastatic Pleural Tumor, Ovarian Cancer, Orchiectomy, and Prostatectomy.

His clinical research consists of co-authoring 248 peer reviewed articles and participating in 34 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

MD Anderson
1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Biological
Study Drugs: IPN60090, Pembrolizumab
Study Phase: Phase 1
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel
Study Phase: Phase 1
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Phase: Phase 1/Phase 2
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Copanlisib, Ipilimumab, Nivolumab
Study Phase: Phase 1
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Copanlisib, Fulvestrant
Study Phase: Phase 2
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drug: FS118
Study Phase: Phase 1/Phase 2
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB)
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB)
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Biological
Study Drugs: SRK-181, Anti-PD-(L)1 Antibody Therapy
Study Phase: Phase 1
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: ART4215, Talazoparib, Niraparib
Study Phase: Phase 1
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)
A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: CYT-0851
Study Phase: Phase 1/Phase 2
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Advanced or Metastatic Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: NIR178, PDR001
Study Phase: Phase 2
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients with Advanced Solid Tumours
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients with Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: September 26, 2024
Intervention Type: Drug
Study Phase: Phase 1
PIPA: a Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination with PAlbociclib, with the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers
PIPA: a Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination with PAlbociclib, with the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers
Enrollment Status: Completed
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Taselisib/Pictilisib
Study Phase: Phase 1
An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study
An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study
Enrollment Status: Terminated
Publish Date: May 30, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Enrollment Status: Terminated
Publish Date: March 21, 2024
Intervention Type: Drug
Study Drug: CYH33
Study Phase: Phase 1
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drugs: Rucaparib, Lucitanib, Sacituzumab govitecan
Study Phase: Phase 1/Phase 2
Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab
Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab
Enrollment Status: Terminated
Publish Date: August 14, 2023
Intervention Type: Biological
Study Phase: Phase 1
Strategic Alliance: Phase 1b Trial of the Combination of the ATR Inhibitor BAY1895344 and PI3K Inhibitor Copanlisib in Molecularly Selected Patients With Advanced Solid Tumors (COPABAY)
Strategic Alliance: Phase 1b Trial of the Combination of the ATR Inhibitor BAY1895344 and PI3K Inhibitor Copanlisib in Molecularly Selected Patients With Advanced Solid Tumors (COPABAY)
Enrollment Status: Withdrawn
Publish Date: May 27, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 30 Less Clinical Trials

248 Total Publications

Drugging the DNA damage response in the clinic: going beyond PARP.
Drugging the DNA damage response in the clinic: going beyond PARP.
Journal: Expert review of anticancer therapy
Published: October 14, 2025
Similar Doctors
Elite in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Arlene O. Siefker-Radtke
Oncology
Elite in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Arlene O. Siefker-Radtke
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Arlene Siefker-Radtke is an Oncologist in Houston, Texas. Dr. Siefker-Radtke is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Lymphadenectomy.

Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Seth P. Lerner
Urology | Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Seth P. Lerner
Urology | Oncology

Baylor College Of Medicine

7200 Cambridge St, 
Houston, TX 
 (0.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Seth Lerner is an Urologist and an Oncologist in Houston, Texas. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Eric A. Jonasch
Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Eric A. Jonasch
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jonasch is an Oncologist in Houston, Texas. Dr. Jonasch is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Renal Cell Carcinoma (RCC), Hemangioblastoma, Chromophobe Renal Cell Carcinoma, Hypothalamic Hamartomas, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yap's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile